Particularly serious crime

NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference

Retrieved on: 
Tuesday, October 5, 2021
Well, Securities Act of 1933, Bird, COVID-19, CMC, Conference, Hepatitis C, Virus, Consultant, Food and Drug Administration, Advanced Therapy Medicinal Product, IND, Safety, EKC, EMA, Hepatitis B virus, Food, Market capitalization, European Medicines Agency, Drug Quality and Security Act, Multimedia, Technology, Good manufacturing practice, Animal, HCV, Coronavirus diseases, NYSE, HIV, HBV, Dengue fever, Gilead, Shingles, Particularly serious crime, Risk, CGMP, Committee, Degenerative disease, FDA, Human body weight, U.S. Securities and Exchange Commission, Control, Cell, Company, Pandemic, Corporation, Influenza, VZV, Eye, Investigational New Drug, US FDA, Patient, CHMP, Committee for Medicinal Products for Human Use, Keratitis, Drug development, Securities Exchange Act of 1934, US, Pharmaceutical industry, Vaccine

The Benzinga Healthcare Small Cap Conference bridges the gap between Small Cap companies, investors, and traders.

Key Points: 
  • The Benzinga Healthcare Small Cap Conference bridges the gap between Small Cap companies, investors, and traders.
  • Learn about small cap investing with clearly defined Educational Modules, take a look at a curated group of Small Cap investment opportunities, and connect with the healthcare Small Cap audience in an intimate, virtual setting.
  • We invite investors and all interested parties to explore healthcare small cap investment opportunities through two days of networking, dealmaking and discovery.
  • The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.

NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference

Retrieved on: 
Tuesday, October 5, 2021
Well, Securities Act of 1933, Bird, COVID-19, CMC, Conference, Hepatitis C, Virus, Consultant, Food and Drug Administration, Advanced Therapy Medicinal Product, IND, Safety, EKC, EMA, Hepatitis B virus, Food, Market capitalization, European Medicines Agency, Drug Quality and Security Act, Technology, Good manufacturing practice, Animal, HCV, Coronavirus diseases, NYSE, HIV, HBV, Dengue fever, Gilead, Shingles, Particularly serious crime, Risk, CGMP, Committee, Degenerative disease, FDA, Human body weight, U.S. Securities and Exchange Commission, Control, Cell, Company, Pandemic, Corporation, Influenza, VZV, Eye, Investigational New Drug, US FDA, Patient, CHMP, Committee for Medicinal Products for Human Use, Keratitis, Drug development, Securities Exchange Act of 1934, US, Pharmaceutical industry, Vaccine

The Benzinga Healthcare Small Cap Conference bridges the gap between Small Cap companies, investors, and traders.

Key Points: 
  • The Benzinga Healthcare Small Cap Conference bridges the gap between Small Cap companies, investors, and traders.
  • Learn about small cap investing with clearly defined Educational Modules, take a look at a curated group of Small Cap investment opportunities, and connect with the healthcare Small Cap audience in an intimate, virtual setting.
  • We invite investors and all interested parties to explore healthcare small cap investment opportunities through two days of networking, dealmaking and discovery.
  • The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.